In vitro effects of tibolone and its metabolites on human vascular coronary cells

Maturitas

Volumn 58, Issue 1, 2007, Pages 42-49

  Seeger, H ^a   Kloosterboer, H J ^b   Studen, M ^b   Wallwiener, D ^a   Mueck, A O ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Organon ^*  (Netherlands)

Author keywords

Endothelial cells; Smooth muscle cells; Tibolone; Vascular markers

Indexed keywords

3ALPHA HYDROXYTIBOLONE; 3BETA HYDROXYTIBOLONE; 6 OXOPROSTAGLANDIN F1 ALPHA; ADENOSINE TRIPHOSPHATE; ANTIESTROGEN; DELTA4 TIBOLONE; DRUG METABOLITE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ESTRADIOL; INTERCELLULAR ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; MEDROXYPROGESTERONE ACETATE; MONOCYTE CHEMOTACTIC PROTEIN 1; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NORETHISTERONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; TIBOLONE; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; ENDOTHELIUM CELL; ESTROGEN ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MENOPAUSAL SYNDROME; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; VASCULAR SMOOTH MUSCLE;

BIOLOGICAL MARKERS; CELLS, CULTURED; CORONARY VESSELS; E-SELECTIN; ENDOTHELINS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPOPROSTENOL; ESTRADIOL; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MATRIX METALLOPROTEINASE 1; MEDROXYPROGESTERONE 17-ACETATE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; NORETHINDRONE; NORPREGNENES; PLASMINOGEN ACTIVATOR INHIBITOR 1; VASCULAR RESISTANCE;

EID: 34547958741     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2007.04.011     Document Type: Article

References (25)

1. Albertazzi P., Di Micco R., and Zanardi E. Tibolone: a review. Maturitas 30 (1998) 295-305
2. Kloosterboer H.J. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 30 (2004) S30-S40
3. Volker W., CoelinghBennink H.J., and Helmond F.A. Effects of tibolone on the endometrium. Climacteric 4 (2001) 203-208
4. Von Schoultz B. The effects of tibolone and oestrogen-based HT on breast cell proliferation and mammographic density. Maturitas 49 (2004) S16-S21
5. Conner P., Christow A., Kersemaekers W., et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen-progestogen treatment. Climacteric 7 (2004) 50-58
6. Moore R.A. Livial: a review of clinical studies. Br J Obstet Gynecol 106 Suppl 19 (1999) 1-21
7. Winkler U.H., Altkemper R., Kwee B., Helmond F.A., and Coelingh-Bennink H.J. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 74 (2000) 10-19
8. Simoncini T., Mannella P., Fornari L., et al. Tibolone activates nitric oxide synthesis in human endothelial cells. J Clin Endocrin Metab 89 (2004) 4594-4600
9. Dubey R.K., Gillespie D.G., Grögli M., Kloosterboer H.J., and Imthurn B. Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: role of estrogen, progesterone, and androgen receptors. J Clin Endocrin Metab 89 (2004) 852-859
10. Drexler H. Endothelial dysfunction: clinical Implications. Prog Cardiovasc Dis 39 (1997) 287-324
11. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 (2002) 321-333
12. The Women's Health Initiative Steering Committee. Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy. The Women's Health Initiative Randomised Controlled Trial. JAMA 291 (2004) 1701-1712
13. Haenggi W., Bersinger N.A., Mueller M.D., and Birkhäuser M.H. Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone. Gynecol Endocrinol 3 (1999) 202-205
14. Zandberg P., Peters J.L.M., Demacker P.N., et al. Comparison of the antiatherosclerotic effect of tibolone with that of estradiol and ethinyl estradiol in cholesterol-fed, ovariectomized rabbits. Menopause 8 (2001) 96-105
15. Castelo-Branco C., Garcia-Fantini M., and Hava J. Vascular reactivity and atheromatous plaques in postmenopausal women on tibolone treatment. Open prospective study with Doppler ultrasonography in internal carotid artery. Maturitas 50 (2005) 259-265
16. Mikkola T.S., Anthony M.S., Clarkson T.B., and St Clair R.W. Serum cholesterol efflux potential is an independent predictor of coronary artery atherosclerosis. Atherosclerosis 170 (2003) 31-38
17. Lakoski S.G., and Herrington D.M. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Climacteric 8 (2005) 317-326
18. Bots M.L., Evans G.W., Riley W., et al. for the OPAL investigators. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J (Adv Access) (2006) 10.1093/eurheartj/ehi695
19. Clarkson T.B. Does tibolone exacerbate atherosclerosis?. Eur Heart J 27 (2006) 635-637
20. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 138 (1999) S419-S420
21. Simoncini T., and Genazzani A.R. Tibolone inhibits leucocyte adhesion molecule expression in human endothelial cells. Mol Cell Endocrinol 162 (2000) 87-94
22. Sator K., Sator M.O., Sator P.G., Egarter C., and Huber J.C. Effects of tibolone on selectins in postmenopausal women. Maturitas 53 (2006) 166-170
23. Bjarnason N.H., Bjarnason K., Haarbo J., Bennink H.J., and Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 82 (1997) 1752-1756
24. Koh K.K., Han S.H., Shin M.S., Ahn J.Y., Lee Y., and Shin E.K. Signifiant different effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomizd, double-blind, crossover study. Eur Heart J 26 (2005) 1362-1368
25. Cummings S.R. LIFT study is discontinued. Br Med J 332 (2006) 667